Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SYRE vs ROIV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ROIV Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 4–3 Matrix Metrics)

ROIV Overall Winner 6-Pillar Tally: SYRE 1 – 3 ROIV (2 Tie) Matrix Metrics: SYRE 3 – 4 ROIV

As of Nov 16, 2026, Roivant Sciences Ltd. Common Shares (ROIV) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). SYRE carries a Unified Composite Score of 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas ROIV carries 39.6/100 (SELL) at $38.77 (N/M Forward P/E, -3226.3% operating margin).

  • Composite vs. Pillar Nuance: While SYRE currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. ROIV 39.6/100 SELL), ROIV captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-3226.3% vs. 0.0% operating margin) and revenue trajectory (+2135.6% vs. +0.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SYRE vs ROIV
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.75β · 59% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70
ROIV NASDAQ Head-to-Head Winner
Roivant Sciences Ltd. Common Shares
Pharmaceutical Preparations
$38.77
-1.92% 1D
Market Cap $28.7B
TTM Revenue $41M
Forward P/E N/M
Beta / 30D Vol 1.04β · 49% Vol
Unified Composite Score
39.6 / 100 SELL
Tech 15.0 Fund 36.0 Flow 65.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.1% over 20 days), RSI 54
RSI-14: 53.8 · SMA20: $37.87 · SMA50: $37.38

6-Pillar Scorecard Institutional Category Breakdown (SYRE 1 – 3 ROIV)

Columns: Metric · SYRE · ROIV
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale ROIV
Revenue Growth (YoY) +0.0% +2135.6%
Earnings Growth (YoY) -99.7% -96.1%
TTM Revenue (USD) N/A $41M
Market Cap $9.8B $28.7B
3. Profitability & Quality SYRE
Gross Margin N/A N/A
Operating Margin 0.0% -3226.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -35.0% -8.5%
4. Balance Sheet & Cash Flow ROIV
Cash Generation (TTM) N/A -$33M
Cash Flow Margin N/A -81.2%
Net Cash / Leverage $10.06 Book/Sh · -35.0% ROE $5.55 Book/Sh · -8.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ROIV
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 87.9% (10th %ile) 48.1% (7th %ile)
Put/Call OI Skew N/A 0.01x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SYRE (3) vs ROIV (4)
Institutional Metric SYRE ROIV Criterion Row Edge
Market Capitalization
Scale
$9.8B $28.7B Larger Scale ROIV
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +2135.6% Higher Growth ROIV
Operating Margin (TTM)
Profitability
0.0% -3226.3% Higher Margin SYRE
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-35.0% -8.5% Higher ROE ROIV
52-Week Range Position
Momentum
88% ($22–$111) 84% ($20–$42) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.75β · 59% Vol 1.04β · 49% Vol Lower Realized Risk ROIV
Unified Institutional Score
Composite Signal
44.4 / 100 (HOLD) 39.6 / 100 (SELL) Higher Composite SYRE
Trailing 12M Revenue (USD)
Operating Scale
N/A $41M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($10.06 Book/Sh · -35.0% ROE) -$33M ($5.55 Book/Sh · -8.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +9.48 pp
SYRE: +25.11% · ROIV: +15.63%
3M Horizon ROIV +11.04 pp
SYRE: -7.29% · ROIV: +3.75%
6M Horizon SYRE +6.84 pp
SYRE: +42.64% · ROIV: +35.8%
1Y Horizon SYRE +253.17 pp
SYRE: +341.74% · ROIV: +88.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs ROIV. Trailing 12-month operating profitability (SYRE 0.0% vs ROIV -3226.3%) and valuation multiples (SYRE N/M vs ROIV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M
ROIV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$41M
Gross MarginN/A
Op. Margin-3226.3%
ROE / Fwd P/E-8.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ROIV CONSOLIDATION
48d in phase · OBV ACCUMULATION
Current IV 48.1%
IV Percentile 7th %ile
Put/Call OI Skew 0.01x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ROIV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ROIV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $28.7B market capitalization and -3226.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SYRE vs ROIV Key Questions & Quantitative Answers

As of Nov 16, 2026, Roivant Sciences Ltd. Common Shares (ROIV) is the stronger overall head-to-head candidate over Spyre Therapeutics, Inc. (SYRE) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). SYRE carries a Unified Composite Score of 44.4/100 (HOLD) at $99.97 (N/M Forward P/E, 0.0% operating margin), whereas ROIV carries 39.6/100 (SELL) at $38.77 (N/M Forward P/E, -3226.3% operating margin). Composite vs. Pillar Nuance: While SYRE currently prints a higher short-term Unified Composite Score (44.4/100 HOLD vs. ROIV 39.6/100 SELL), ROIV captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-3226.3% vs. 0.0% operating margin) and revenue trajectory (+2135.6% vs. +0.0% YoY).

ROIV leads the Growth & Scale pillar: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ROIV at +2135.6% YoY revenue growth and -96.1% YoY earnings growth on $41M TTM revenue (N/A gross margin, -3226.3% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus $41M for ROIV. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ROIV.

SYRE and ROIV trade at balanced relative valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ROIV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-81.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus ROIV (-8.5% ROE) capital efficiency.

In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.75β · 59% Vol realized risk). By comparison, ROIV carries 48.1% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.01x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.